Maichuan Health Files IPO Prospectus, Offering Integrated Solutions for Global Pharma Giants Including Pfizer, GSK, Roche, Sanofi, and MSD
The process of launching a new drug is one of breaking through numerous barriers. To expand drug accessibility and educate physicians and patients, health communication platforms serve as a key hub connecting medications with people.
Whether it is the professionalism and compliance requirements for prescription drug marketing, or the need for emerging innovative drugs to gain visibility among physicians and patients, the domestic market requires platforms capable of addressing the diverse needs of pharmaceutical companies. However, compared with the mature development of healthcare agency brands abroad, Chinese companies remain in a fragmented stage. There is nearly a 20-year gap between the domestic and international markets. At this stage, meeting the needs of pharmaceutical companies requires integrated platforms, and breaking through industry development bottlenecks demands collaborative efforts.
At this untapped intersection, Maichuan Health has consolidated seven previously fragmented health brand communication firms to establish the Maichuan Health Communication Group. By entering the upstream and downstream segments of the industry chain as a flagship platform, the group is committed to becoming a leading player in China in terms of client coverage and sales scale within this sector. Currently, Maichuan Group has secured a multi-million-dollar investment from Qianji Capital. Below, you will learn:
1. Reasons Why Pharmaceutical Companies Are Facing Marketing Transformation;
2. How Maichuan Health Provides Comprehensive Solutions for Pharmaceutical Companies;
3. Major Advantages After Integration into the Group;
4. Two Major Plans for the Future of Maichuan Health.
Due to the professional and regulatory requirements for prescription drugs, this is an industry with high entry barriers. However, compared to the mature development of overseas health brand distribution, it is also an industry with enormous growth potential. This market can even rival the R&D market in scale. According to Wind data, in 2017, 11 listed pharmaceutical companies in China reported sales expenses exceeding RMB 1 billion each. For 53 pharmaceutical companies, sales expenses accounted for more than 30% of their revenue, while multinational pharmaceutical companies typically spend nearly 10% of their annual revenue on marketing and promotion.
Abroad, specialized pharmaceutical brand agencies such as Digitas Health LifeBrands, Intouch Solutions, and Klick Health were established in the last century. According to the Top 100 Healthcare Marketing Agencies list evaluated by the leading U.S. pharmaceutical marketing magazine, Medical Marketing & Media, the combined revenue of these 100 companies grew from $2.2 billion in 2016 to $2.5 billion in 2017.
In the domestic market, there is a growing demand for specialization and precision in pharmaceutical marketing on the supply side; however, the supply side remains fragmented, making it impossible to resolve the industry’s inherent problems.
On the demand side, differentiation among pharmaceutical companies’ needs is intensifying, and overall demand continues to grow. This represents a fertile yet thorny landscape that has not been fully explored. First, between multinational pharmaceutical companies and domestic firms, the Chinese market has become a cornerstone of revenue growth for multinationals. In 2017, China became AstraZeneca’s second-largest service market; for Roche’s diagnostics business, the Chinese market contributed 21% of its growth rate, compared with only 2% in Europe.
Furthermore, as the domestic market continues to release increasingly favorable policies, regulations such as the "Opinions on Deepening the Reform of the Review and Approval System to Encourage Innovation in Drugs and Medical Devices," the "Amendment to the Drug Administration Law of the People's Republic of China," and the "Provisions for the Administration of Drug Clinical Trial Institutions" have accelerated the approval process for new drugs, creating conditions for a large number of innovative drugs to enter the domestic market. Previously, there was a lag of up to 7–8 years between a new drug’s launch in Europe and the United States and its subsequent launch in China. Now, AstraZeneca’s third-generation targeted therapy for lung cancer received CFDA approval in just seven months—a historic first.
The removal of policy barriers and market approval merely mark the beginning of a drug’s journey. Prescription medications require better understanding by both physicians and patients. Even physicians, burdened by heavy workloads and information overload, need access to professional and effective drug-related information. Patients also increasingly demand information symmetry and transparency in medication use. When individuals fall ill, their initial response is often to seek relevant information online, and they may even self-assess treatment options. Pharmaceutical marketing should likewise empower patients. The goal is to facilitate the rational flow of authentic, specialized, and effective medical information between physicians and patients.
Marketing remains equally critical for drugs that are already on the market and approaching patent expiration. Zhang Xiaodong, CEO of Maichuan Health Group, stated, “In the late post-launch phase, after the patent protection period expires, numerous competitive generic products emerge. At this stage, the brand reputation and services of pharmaceutical companies become key differentiators.”
Multinational pharmaceutical companies are also the primary payers for Maichuan Health’s current services. Because multinational pharmaceutical firms prioritize specialized promotion in their marketing models and adhere to strict internal compliance requirements, they demonstrate a stronger willingness to pay for drug marketing and agency services. The CEO of Maichuan Health Communication Group also revealed to VCBeat that their clients currently cover 90% of the top 20 multinational pharmaceutical companies. Industry giants such as Pfizer, AstraZeneca, Roche, GSK, Sanofi, Bayer, and Takeda Pharmaceutical have all chosen to partner with Maichuan Group.
Domestic pharmaceutical companies are also facing marketing transformation. With the implementation of the Two-Invoice System, traditional marketing approaches must evolve. As tiered diagnosis and treatment and prescription outflow continue to develop, the traditional medical representative model can no longer effectively cover the primary care market. Demand among domestic pharmaceutical companies for compliance and transparent marketing practices will likewise increase.
This vast market is not an easy prize to claim; rather, it resembles a tough nut to crack. Leveraging its specialized resources and extensive industry experience, Maichuan Health Communication Group provides pharmaceutical companies with comprehensive solutions. On one hand, it integrates existing operations, extending channels and resources to build professional, influential platforms and services for pharmaceutical enterprises. On the other hand, it expands its business scope and develops new business models to deliver more diverse, flexible, and precise services to pharmaceutical companies.
Maichuan Health explained its business model to VCBeat, stating, “We also formulate an annual strategy for them based on market dynamics: What should be done in the first year? And by the second year, or when the brand reaches a more mature stage, how should it be maintained? We help pharmaceutical companies build their brands and develop strategies to sustain their influence.”
In integrating traditional business operations, particularly in physician-focused market education, Maichuan Health Communications can produce a wide range of professional educational materials to provide pharmaceutical sales representatives with diverse resources for their visits to doctors. Furthermore, Maichuan Health can organize numerous professional educational seminars, training sessions, or creative events held in various formats and locations across the country, thereby assisting pharmaceutical companies in their market education efforts.
In expanding its new business ventures, Maichuan Group has integrated seven existing health communication companies to break through development bottlenecks, explore new business models, and develop digital marketing channels. Currently, Maichuan Health has launched Yidao, a professional learning app for physicians, offering specialized content tailored to different medical fields and specialties. VCBeat has previously reported that some pharmaceutical companies’ self-built online marketing platforms have underperformed. The primary reason for the limited effectiveness of these in-house platforms is the lack of high-quality content, which fails to capture physicians’ attention or retain their engagement.
In terms of content development, Zhang Xiaodong, CEO of Maichuan Health, is a former physician who understands the specialized needs of medical professionals. Maichuan Health collaborates with leading medical institutions in China to provide educational and learning resources tailored to specific departments and diseases. Currently, Maichuan Group has partnered with Huashan Hospital Affiliated to Fudan University to launch its first product in the field of infectious diseases.
“Why partner with them? Because they have ranked first in China for seven consecutive years in this field. We prioritize the authority and professionalism of our content. Doctors can take courses through our platform, which also enables us to interact with them,” Zhang Xiaodong explained to VCBeat.
In its future plans, Maichuan Group will also launch an education platform for patients. It will address the different needs of doctors and patients with targeted solutions.
The era of lone-wolf operations is over. In the past, individuals sought their own pieces of cheese within a maze; today, collective effort is required to pry an entire block of cheese from the outside. Generally, mergers and acquisitions (M&A) integration resembles a war without smoke or a money-burning arms race. However, at Maichuan Group, Zhang Xiaodong relies on accumulated rapport and shared goals to drive successful integration.
Maichuan’s integration process began last July and August, but its true origins date back 20 years ago, when Zhang Xiaodong, with a medical background, became one of the first practitioners in China’s pharmaceutical marketing sector. As a veteran in pharmaceutical marketing, Zhang Xiaodong has mentored numerous capable professionals who have since established their own companies. Currently, the management teams of the seven companies integrated under Maichuan Group generally share historical ties with Zhang Xiaodong.
Following the restructuring of the seven original companies, Maichuan Group’s subsidiaries will retain their respective sub-brands and operate independently, fostering healthy competition. Through this consolidation, Maichuan Group will leverage synergies to achieve a “1+1>2” effect, uniting its strengths to establish itself as China’s largest pharmaceutical brand distribution platform.
Integration has become a major global trend in health communication branding. According to the leading pharmaceutical marketing magazine *Medical Marketing & Media*, health brand agencies have undergone a series of structural changes, including large-scale reorganizations, to capture a larger share of the booming health market. Meanwhile, these restructuring efforts have proven effective, with the revenue of the top 100 health agencies ranked by *Medical Marketing & Media* increasing by nearly 14%.
Zhang Xiaodong outlined to VCBeat several key advantages of the group’s integration: “First, it enables us to break through existing business models. Although the seven companies are currently engaged in traditional businesses, their small scale makes it difficult to identify new opportunities and develop new models from an industry-wide perspective. Second, we can provide more comprehensive solutions to meet higher-level demands. By consolidating resources, the group can now leverage its collective strength to undertake larger projects and deliver optimized solutions through internal collaboration mechanisms. Third, integration reduces internal costs, enhances bargaining power with suppliers, and further drives down expenses. Additionally, it establishes a robust internal talent development mechanism and provides greater room for professional growth.”
Abroad, WPP, the world’s largest communications group with subsidiaries such as Ogilvy, J. Walter Thompson, and Mindshare, has also developed along this integrated model. Currently, Maichuan Health Communications Group has received a $10 million investment from Qianji Investment Management Co., Ltd.
Regarding future plans, Maichuan Health has two major strategic initiatives. First, it will leverage the power of integration to further consolidate its health communication subsidiaries. Within this year, Maichuan will also complete the integration of another company.
Second, we are exploring new business models to build a platform that can accumulate resources and value. Zhang Xiaodong explained to VCBeat, “Now that we have this platform, all our previous work will be consolidated on it, making the platform increasingly valuable. In addition, we are exploring new business initiatives by leveraging new methods aligned with technological advancements. We are also investing significant effort in what is known as digital marketing.”
Zhang Xiaodong stated, “Driven by policy and market forces, health communication companies like ours are presented with significant opportunities. As among the first practitioners in China in this field, we bear the responsibility and obligation to foster the development of this industry. This is precisely the original intention behind our endeavors.”